公开(公告)号：US20240335550A1

公开(公告)日：2024-10-10

申请号：US18628261

申请日：2024-04-05

Applicant: Sleep Solutions of Texas, LLC

Inventor： Raghavendra Vitthalrao GHUGE

IPC: A61K47/64 ,  A61K9/00 ,  A61K9/70 ,  A61K31/165 ,  A61K31/513 ,  A61K31/573 ,  A61K31/58 ,  A61K41/00

CPC classification number: A61K47/6435 ,  A61K9/006 ,  A61K9/7007 ,  A61K31/165 ,  A61K31/513 ,  A61K31/573 ,  A61K31/58 ,  A61K41/0042

Abstract: Mucosal patches are disclosed that have a support layer supporting an active layer that has a collagen carbon dot nanocomposite carrying an active agent. The collagen carbon dot nanocomposite is absorbable through a mucosa. The mucosal patches are part of various methods of treatment.

公开(公告)号：US20240316065A1

公开(公告)日：2024-09-26

申请号：US18575619

申请日：2022-07-04

Applicant: Dr Ophelia Limited

Inventor： Ophelia Veraitch

IPC: A61K31/58 ,  A61K9/00 ,  A61K31/203 ,  A61K31/4045 ,  A61K31/506 ,  A61K31/5575 ,  A61P17/14

CPC classification number: A61K31/58 ,  A61K9/0014 ,  A61K31/203 ,  A61K31/4045 ,  A61K31/506 ,  A61K31/5575 ,  A61P17/14

Abstract: A formulation for use in the treatment of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss in a subject that has received or will subsequently or concurrently receive platelet rich fibrin (PRF), said formulation comprising 0.01 wt % to 1 wt % finasteride and 0.01 wt % to 1 wt % melatonin administered to the scalp of the subject. A formulation for use in the treatment of increasing hair thickness, increasing hair growth, reducing hair thinning and/or reducing hair loss of the eyebrows and/or eyelashes of a subject, said formulation comprising 0.01 wt % to 1 wt % finasteride and 0.01 wt % to 1 wt % melatonin administered to the eyebrows and/or eyelashes of the subject.

公开(公告)号：US20240307414A1

公开(公告)日：2024-09-19

申请号：US18267024

申请日：2021-12-21

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Liewei Wang ,  Huanyao Gao

IPC: A61K31/58 ,  A61K31/136 ,  A61K31/454 ,  A61K31/506 ,  A61K31/519 ,  A61K31/704 ,  A61N5/10 ,  A61P35/00 ,  G01N33/574

CPC classification number: A61K31/58 ,  A61K31/136 ,  A61K31/454 ,  A61K31/506 ,  A61K31/519 ,  A61K31/704 ,  A61N5/10 ,  A61P35/00 ,  G01N33/57434

Abstract: This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having prostate cancer. For example, methods and materials for determining whether or not a prostate cancer is likely to respond to a particular cancer treatment (e.g., an anti-androgen agent) are provided. Methods and materials for using one or more cancer treatments to treat a mammal (e.g., a human) identified as likely to respond to a particular cancer treatment are also provided.

公开(公告)号：US20240245690A1

公开(公告)日：2024-07-25

申请号：US18627415

申请日：2024-04-04

Applicant: TIANLI BIOTECH PTY LTD

Inventor： Alastair Stewart ,  Christine Keenan ,  Trudi Harris

IPC: A61K31/519 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61P35/00 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D487/04

CPC classification number: A61K31/519 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61P35/00 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D487/04

Abstract: The present invention relates to compositions, methods and kits for the treatment of respiratory disease. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment or prevention of exacerbations of asthma and chronic obstructive pulmonary disease. The present invention provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1, thereby treating or preventing a respiratory disease in a subject. The present invention also provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of ALK5, thereby treating or preventing a respiratory disease in a subject, wherein the inhibitor is administered directly to the airway and/or lungs. The present invention also provides a method of treating or preventing a condition of the airway or lung involving fibrosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1 or an inhibitor of ALK5, thereby treating or preventing a condition of the airway or lung involving fibrosis in a subject.

公开(公告)号：US20240226006A1

公开(公告)日：2024-07-11

申请号：US18425676

申请日：2024-01-29

Applicant: Covis Pharma GmbH

Inventor： Helgert Müller ,  Renate Engelstätter ,  Ulrich Bildmann ,  Andrea Bauer ,  Paul McGlynn

IPC: A61K9/12 ,  A61K9/00 ,  A61K31/58 ,  A61M11/04 ,  A61M15/00

CPC classification number: A61K9/124 ,  A61K9/008 ,  A61K31/58 ,  A61M11/04 ,  A61M15/0001 ,  A61M15/0065 ,  A61M15/009

Abstract: This invention relates to a pharmaceutical aerosol product suitable for administration by oral or nasal inhalation and its use in the treatment of respiratory diseases, in particular in the treatment of children. The aerosol composition comprises ciclesonide, ethanol and either 1,1,1,2-tetrafluoroethane, or 1,1,1,2,3,3,3-heptafluoropropane.

公开(公告)号：US20240216395A1

公开(公告)日：2024-07-04

申请号：US18557691

申请日：2022-04-29

Applicant: Sage Therapeutics, Inc.

Inventor： Robert Alfonso Lasser ,  James Doherty ,  Jeffrey Martin Jonas ,  Stephen Jay Kanes ,  Handan Gunduz-Bruce ,  Helen Anne Colquhoun ,  Ryan Arnold ,  Vijayveer Bonthapally ,  Joi Lisa Dunbar ,  Bambang Senoaji Adiwijaya

IPC: A61K31/58 ,  A61K45/06 ,  A61P25/22 ,  A61P25/24

CPC classification number: A61K31/58 ,  A61K45/06 ,  A61P25/22 ,  A61P25/24

Abstract: The present disclosure relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof. The disclosure also relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating postpartum depression (PPD) with elevated anxiety in a subject in need thereof.

公开(公告)号：US12023348B2

公开(公告)日：2024-07-02

申请号：US15569407

申请日：2016-04-26

Applicant: The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center

Inventor： Ofer Sarig ,  Eli Sprecher

IPC: A61K31/704 ,  A61K31/122 ,  A61K31/137 ,  A61K31/167 ,  A61K31/277 ,  A61K31/365 ,  A61K31/366 ,  A61K31/37 ,  A61K31/404 ,  A61K31/423 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4402 ,  A61K31/4453 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4738 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/498 ,  A61K31/53 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/566 ,  A61K31/58 ,  A61K31/688 ,  A61K45/06 ,  A61P17/00 ,  A61P17/06

CPC classification number: A61K31/704 ,  A61K31/122 ,  A61K31/137 ,  A61K31/167 ,  A61K31/277 ,  A61K31/365 ,  A61K31/366 ,  A61K31/37 ,  A61K31/404 ,  A61K31/423 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4402 ,  A61K31/4453 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/4738 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/498 ,  A61K31/53 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/566 ,  A61K31/58 ,  A61K31/688 ,  A61K45/06 ,  A61P17/00 ,  A61P17/06

Abstract: A method of treating an inflammation or a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:



a compound represented by Formula I:








or a pharmaceutically acceptable salt thereof,



a compound represented by Formula II:










and a compound represented by Formula III:








wherein the variables in Formulae I, II and III are as defined in the specification.

公开(公告)号：US12016926B2

公开(公告)日：2024-06-25

申请号：US16772273

申请日：2018-12-07

Applicant: BASF SE

Inventor： Ferdinand Paul Brandl ,  Theo Smit ,  Felicitas Guth ,  Karl Kolter ,  Maximilian Angel ,  Frank Schmidt

IPC: A61K9/16 ,  A61K31/216 ,  A61K31/5377 ,  A61K31/58 ,  A61K31/635 ,  A61K47/32 ,  C08F220/06 ,  C08F220/18 ,  C08F226/10

CPC classification number: A61K47/32 ,  A61K9/1635 ,  A61K31/216 ,  A61K31/5377 ,  A61K31/58 ,  A61K31/635 ,  C08F220/06 ,  C08F220/1803 ,  C08F220/1804 ,  C08F220/1806 ,  C08F226/10 ,  C08F220/1803 ,  C08F220/06 ,  C08F226/10 ,  C08F220/1806 ,  C08F220/06 ,  C08F226/10 ,  C08F220/1804 ,  C08F220/06 ,  C08F220/301

Abstract: Terpolymer, wherein 20 to 35% by weight of the structural units are derived from acrylic acid, 45 to 60% by weight of the structural units from a hydrophobic methacrylate selected from a group consisting of isopropyl methacrylate, tert-butyl methacrylate and cyclohexyl methacrylate and 15 to 40% by weight of the structural units from a third olefinic monomer selected from the group consisting of N-vinyl lactam, hydroxy ethyl methacrylate and phenoxyethyl acrylate with the proviso that the total amount of structural units derived from the three monomer groups adds up to 100% by weight, and the use of the terpolymers as crystallization inhibitors in pharmaceutical dosage forms for inhibiting the recrystallization in an aqueous environment of a human or animal body of an active ingredient.

公开(公告)号：US20240197639A1

公开(公告)日：2024-06-20

申请号：US18287244

申请日：2022-04-20

Applicant: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Inventor： Haifeng SUN ,  Weibi WANG ,  Wei WANG ,  Jie WANG ,  Xiaoli CAO ,  Zhirong MO

IPC: A61K9/48 ,  A61K31/198 ,  A61K31/58

CPC classification number: A61K9/4866 ,  A61K9/4808 ,  A61K9/4825 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4891 ,  A61K31/198 ,  A61K31/58

Abstract: A capsule for specific drug delivery and a preparation method therefor, relating to a capsule containing a non-liquid filler and a modified release coating. The modified release coating covers a capsule shell, an isolating layer is provided between the capsule shell and the modified release coating, and no sealing film is provided between the body and cap of the capsule. The capsule can be used for delivering a drug to an intestinal track, and exhibits excellent characteristics in mass production of capsules and drug release.

公开(公告)号：US20240180900A1

公开(公告)日：2024-06-06

申请号：US18493773

申请日：2023-10-24

Applicant: Arvinas Operations, Inc.

Inventor： Ronald PECK ,  Sarah Deborah CHIRNOMAS ,  Edward CHAN ,  Richard Walter GEDRICH ,  Elmer J. BERGHORN, Jr. ,  Jeanette Toni ALICEA ,  Lawrence B. SNYDER ,  SangHyun LEE ,  Taavi NEKLESA

IPC: A61K31/496 ,  A61K31/573 ,  A61K31/58 ,  A61P35/00

CPC classification number: A61K31/496 ,  A61K31/573 ,  A61K31/58 ,  A61P35/00

Abstract: This disclosure pertains to methods of treating prostate cancer in a subject, including prostate cancer comprising at least one somatic AR tumor mutation, such as metastatic prostate cancer, castrate-resistant prostate cancer, metastatic castrate-resistant prostate cancer, progressive metastatic castrate-resistant prostate cancer, castrate-sensitive prostate cancer, metastatic castrate-sensitive prostate cancer, prostate cancer naïve to novel hormonal agents (NHAs), metastatic prostate cancer naïve NHAs, castrate-resistant prostate cancer naïve to NHAs, castrate-sensitive prostate cancer naïve to NHAs, metastatic castrate-resistant prostate cancer naïve to NHAs, and metastatic castrate-sensitive prostate cancer naïve to NHAs, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof.